JP2007532134A5 - - Google Patents

Download PDF

Info

Publication number
JP2007532134A5
JP2007532134A5 JP2007508442A JP2007508442A JP2007532134A5 JP 2007532134 A5 JP2007532134 A5 JP 2007532134A5 JP 2007508442 A JP2007508442 A JP 2007508442A JP 2007508442 A JP2007508442 A JP 2007508442A JP 2007532134 A5 JP2007532134 A5 JP 2007532134A5
Authority
JP
Japan
Prior art keywords
vinyl
ester
group
lipase
rapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007508442A
Other languages
English (en)
Other versions
JP2007532134A (ja
JP4224115B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/012266 external-priority patent/WO2005105811A1/en
Publication of JP2007532134A publication Critical patent/JP2007532134A/ja
Publication of JP2007532134A5 publication Critical patent/JP2007532134A5/ja
Application granted granted Critical
Publication of JP4224115B2 publication Critical patent/JP4224115B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. リパーゼの存在下、42−ヒドロキシラパマイシンをアシル供与体でアシル化することを含む、式(I):
    Figure 2007532134
    (式中、Rは、ヒドロキシル、ハロゲンおよび/またはチオを場合によっては含有する、線状または環状、脂肪族または芳香族、飽和または不飽和炭化水素である)のラパマイシン42−エステル誘導体の位置特異的調製方法。
  2. 使用されるリパーゼが、微生物、例えば、アスペルギルス・ニガー(Aspergillus niger)、カンジダ・アンタルクチカ(Candida antarctica)、カンジダ・ルゴサ(Candida rugosa)、ムコール・ミーヘイ(Mucor miehei)、シュードモナス・セパシア(Pseudomonas cepacia)、シュードモナス・フルオレッセンス(Pseudomonas fluorescens)、リゾープス・デレマ(Rhizopus delemar)からの細菌リパーゼである、請求項1に記載の方法。
  3. 使用されるリパーゼが、B型カンジダ・アンタルクチカ(Candida antarctica type B)からのもの(NOVOZYME 435リパーゼ)またはシュードモナス・セパシア(Pseudomonas cepacia)からのもの(リパーゼPS−C「Aamano」II)である、請求項2に記載の方法。
  4. 前記アシル供与体が、ビニルエステル、イソプロペニルエステルまたは無水物である、請求項1から3のいずれか一項に記載の方法。
  5. 前記ビニルエステルが、式CH2=CH−O−COR1(式中、R1は、ヒドロキシル、ハロゲンおよびSHから独立して選択される基で場合によっては置換されている、C1〜C6アルキル、C2〜C6アルケニル、C6〜C14アリール、ベンジルから成る群より選択される)を有する、請求項4に記載の方法。
  6. 前記ビニルエステルが、ビニルアセテート、ビニルプロピオネート、ビニルクロロアセテート、ビニルクロトネート、ビニルベンゾエートおよびビニルデカノエートから成る群より選択される、請求項5に記載の方法。
  7. 前記ビニルエステルが、イソプロピリデン保護ビニル3−ヒドロキシ−2−(ヒドロキシメチル)−2−メチルプロピオネートである、請求項4に記載の方法。
  8. 前記イソプロペニルエステルが、式CH2=C(CH3)−OCOR2(式中、R2は、ヒドロキシル、ハロゲンおよびSHから独立して選択される基で場合によっては置換されている、C1〜C6アルキル、C2〜C6アルケニル、C6〜C14アリール、ベンジルから成る群より選択される)を有する、請求項4に記載の方法。
  9. 前記イソプロペニルエステルが、イソプロペニルアセテートである、請求項8に記載の方法。
  10. 前記無水物が、ハロゲンおよびヒドロキシルから独立して選択される基で場合によっては置換されている、C1〜C8直鎖または分枝鎖アルカン酸無水物である、請求項4に記載の方法。
  11. 前記反応が、トルエン、t−ブチルメチルエーテル(TBME)、エチルエーテル、THF、MeCN、CH2Cl2、CHCl3、ヘキサン、ジオキサンまたはこれらの混合物から成る群より選択される有機溶媒中で行われる、請求項1から10のいずれか一項に記載の方法。
  12. 前記反応が、20℃から75℃の範囲内で行われる、請求項1から11のいずれか一項に記載の方法。
  13. CCI−779の前駆体である、イソプロピリデンケタール保護3−ヒドロキシ−2−(ヒドロキシメチル)−2−メチルプロピオン酸とのラパマイシン42−エステルの位置特異的製剤。
  14. 請求項1から12のいずれか一項に記載の方法に従って製造された位置特異的ラパマイシン42−誘導体を含む組成物もしくは請求項13に記載の位置特異的ラパマイシン42−誘導体製剤を含む組成物、または生理適合性担体をさらに含む該組成物、および該組成物のための容器を含む製品。
  15. 請求項1から12のいずれか一項に従って製造された位置特異的ラパマイシン42−誘導体の複数の単位を単位剤形で含む薬学的キット。
JP2007508442A 2004-04-14 2005-04-12 ラパマイシン42−エステル誘導体の位置特異的合成 Expired - Fee Related JP4224115B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56192604P 2004-04-14 2004-04-14
PCT/US2005/012266 WO2005105811A1 (en) 2004-04-14 2005-04-12 Regiospecific synthesis of rapamycin 42-ester derivatives

Publications (3)

Publication Number Publication Date
JP2007532134A JP2007532134A (ja) 2007-11-15
JP2007532134A5 true JP2007532134A5 (ja) 2008-03-13
JP4224115B2 JP4224115B2 (ja) 2009-02-12

Family

ID=34965235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007508442A Expired - Fee Related JP4224115B2 (ja) 2004-04-14 2005-04-12 ラパマイシン42−エステル誘導体の位置特異的合成

Country Status (23)

Country Link
US (1) US7268144B2 (ja)
EP (1) EP1737869A1 (ja)
JP (1) JP4224115B2 (ja)
KR (1) KR20070015544A (ja)
CN (1) CN1942476A (ja)
AR (1) AR049019A1 (ja)
AU (1) AU2005238431A1 (ja)
BR (1) BRPI0509852A (ja)
CA (1) CA2562952A1 (ja)
CL (1) CL2008000507A1 (ja)
CR (1) CR8646A (ja)
EC (1) ECSP066927A (ja)
GT (1) GT200500085A (ja)
IL (1) IL178315A0 (ja)
MX (1) MXPA06011881A (ja)
NO (1) NO20065090L (ja)
PA (1) PA8629901A1 (ja)
PE (1) PE20060253A1 (ja)
RU (1) RU2387657C2 (ja)
SG (1) SG152234A1 (ja)
TW (1) TW200536542A (ja)
UA (1) UA87492C2 (ja)
WO (1) WO2005105811A1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2493878C (en) 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
WO2005105812A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
CA2562164A1 (en) * 2004-04-27 2005-11-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
BRPI0514206A (pt) * 2004-08-10 2008-06-03 Wyeth Corp composto, anticorpo, kit para monitorar a terapia com cci-779, e, métodos para detectar metabólitos de cci-779, e para produzir um metabólito sintético e um derivado de cci-779
EP1856130A1 (en) * 2005-02-09 2007-11-21 Wyeth a Corporation of the State of Delaware Cci-779 polymorph and use thereof
US7538119B2 (en) * 2005-11-04 2009-05-26 Wyeth 41-Methoxy isotope labeled rapamycin 42-ester
AU2006322030A1 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
JP2009518413A (ja) * 2005-12-07 2009-05-07 ワイス 精製結晶性cci−779を調製するためのプロセス
JP2009518412A (ja) * 2005-12-07 2009-05-07 ワイス ラパマイシン42−エステルボロネートからラパマイシン42−エステルを調製するためのスケーラブルな方法
KR20080106225A (ko) * 2006-03-07 2008-12-04 와이어쓰 마크롤라이드 면역억제제의 수용성 폴리에틸렌 글리콜 콘쥬게이트를 제조하는 방법
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
US20110098241A1 (en) * 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
CN101676291B (zh) * 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
DK2365802T3 (da) 2008-11-11 2017-11-13 Univ Texas Mikrokapsler af rapamycin og anvendelse til behandling af cancer
IT1394309B1 (it) * 2009-05-22 2012-06-06 Poli Ind Chimica Spa Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
BR112013025085A2 (pt) * 2011-04-01 2016-07-19 Sandoz Ag processo para a acilação de rapamicina e processo para sintetizar tensirolimo
CN104203959B (zh) * 2012-06-08 2017-09-15 百多力股份公司 雷帕霉素40‑o‑环状烃酯、组合物和方法
US10751450B2 (en) 2012-06-08 2020-08-25 Biotronik Ag Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
SG11201507406YA (en) 2013-03-15 2015-10-29 Biosensors Int Group Ltd Purification of rapamycin derivatives
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
CA3052479A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
EP3713547A4 (en) * 2017-11-20 2023-07-19 Icahn School of Medicine at Mount Sinai TRAINED IMMUNITY INHIBITION USING A THERAPEUTIC BIOLOGICAL NANO-COMPOSITION
WO2020101675A1 (en) 2018-11-14 2020-05-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
WO2020209828A1 (en) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
US20240100025A1 (en) * 2020-12-14 2024-03-28 Biotronik Ag Materials and Methods for Treating Viral and Other Medical Conditions
MX2023011004A (es) 2021-03-19 2024-01-08 Trained Therapeutix Discovery Inc Compuestos para regular la inmunidad entrenada y métodos para usarlos.
WO2023070605A1 (en) * 2021-10-29 2023-05-04 Trevena, Inc. Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
CN118027062A (zh) * 2023-11-03 2024-05-14 沈阳药科大学 一种雷帕霉素前药及其纳米制剂的制备和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5210030A (en) 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
ES2313983T3 (es) 2000-09-19 2009-03-16 Wyeth Esteres hidrosolubles de rapamicina.
CA2493878C (en) 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
WO2005016935A2 (en) 2003-08-07 2005-02-24 Wyeth Regioselective synthesis of cci-779
CA2536775A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
AU2004314213A1 (en) * 2004-01-08 2005-08-04 Wyeth Directly compressible pharmaceutical composition for the oral admimistration of CCI-779

Similar Documents

Publication Publication Date Title
JP2007532134A5 (ja)
RU2006134014A (ru) Региоспецифический синтез производных 42-эфира рапамицина
González-Sabín et al. Regioselective enzymatic acylation of complex natural products: expanding molecular diversity
Nazir et al. Evaluation of antioxidant and antimicrobial activities of Bergenin and its derivatives obtained by chemoenzymatic synthesis
RU2008134369A (ru) Способы получения водорастворимых конъюгатов полиэтиленгликоля и макролидных иммунодепрессантов
Patti et al. Use of Mucor miehei lipase in the preparation of long chain 3-O-acylcatechins
JP2007532655A (ja) ラパマイシンコンジュゲートおよび抗体のための前駆体である、ジカルボン酸とのラパマイシン42−エステルおよびジカルボン酸とのfk−50632−エステルの調製プロセス
Barbayianni et al. Biocatalyzed Regio‐and Chemoselective Ester Cleavage: Synthesis of Bioactive Molecules
Magnusson et al. Activation of n-3 polyunsaturated fatty acids as oxime esters: a novel approach for their exclusive incorporation into the primary alcoholic positions of the glycerol moiety by lipase
Brahmachari Lipase-catalyzed organic transformations: a recent update
JPH069514B2 (ja) γ―ヒドロキシデカン酸及びγ―デカラクトンの製造方法
Pchelka et al. Resolution of racemic 1-azido-3-aryloxy-2-propanols by lipase-catalyzed enantioselective acetylation
Koszelewski et al. Synthesis of Enantiomerically Pure 5, 6‐Dihydropyran‐2‐ones via Chemoenzymatic Sequential DKR‐RCM Reaction
Mezzetti et al. Highly enantioselective kinetic resolution of primary alcohols of the type Ph-X-CH (CH3)-CH2OH by Pseudomonas cepacia lipase: effect of acyl chain length and solvent
Sebrão et al. Regioselective acylation of d-ribono-1, 4-lactone catalyzed by lipases
JPH1036301A (ja) 酵素によるアシル化
Santaniello et al. Lipase-catalyzed deacylation by alcoholysis: a selective, useful transesterification reaction
CZ286077B6 (cs) Enzymatický způsob stereoselektivní přípravy enantiomeru heterobicyklického alkoholu, čistý enantiomer a jeho použití
Bisht et al. Preparative and mechanistic aspects of inter-estification reactions on diols and peracetylated polyphenolic compounds catalysed by lipases
Truppo et al. A novel resolution of a pharmaceutically important bridged bicyclic ketone intermediate via selective enzymatic reduction with a commercially available ketoreductase
Vallikivi et al. Lipase action on some non-triglyceride substrates
Wang et al. A simple procedure for the synthesis of potential 6-azauridine prodrugs by Thermomyces lanuginosus lipase
Ciuffreda et al. Lipase-catalyzed monoprotection of 1, 4-diols in an organic solvent using vinyl benzoate as acyl transfer agent
Li et al. Unexpected reversal of the regioselectivity in Thermomyces lanuginosus lipase-catalyzed acylation of floxuridine
Pchelka et al. Resolution of racemic 3-aryloxy-1-nitrooxypropan-2-ols by lipase-catalyzed enantioselective acetylation